India’s fifth-largest drugmaker is thriving in diabetes and cardiac care while waiting for its infection-treatment business to recover
Mankind Pharma is executing a textbook transition from acute to chronic therapies, and the third-quarter numbers prove the strategy is working—mostly. The company posted 11.5% revenue growth to Rs 35,672 million, beating estimates, while margins expanded to 25.8%. Yet beneath this solid performance lies a persistent challenge: the acute and anti-infective businesses that once drove growth remain stubbornly soft.
The dichotomy is striking. BP Equities reports “robust growth in cardiac (+16.7%) and anti-diabetes (+14.4%) therapies,” while Systematix notes “the anti infective / acute business is also a drag on overall growth.” This split personality—thriving chronic business, struggling acute segment—defines both the opportunity and the challenge ahead.
The Chronic Transformation Accelerates
Mankind’s pivot to chronic therapies is yielding tangible results. “Mankind’s chronic portfolio share improved by 200 bps YoY to 39.3%,” BP Equities reports, marking a significant compositional shift for a company historically strong in acute treatments and over-the-counter products.
Systematix highlights that “Cardiac therapies and anti-diabetic registered 1.2x outperformance versus the IPM, contributing significantly to the overall growth.” Outpacing the Indian pharmaceutical market by 20% in your fastest-growing segments demonstrates genuine competitive momentum.
Specific therapeutic areas show impressive traction. BP Equities notes the “immunotherapy & inhaler portfolio performed well; key brands like Symbicort/Combihale reported ~30% growth.”
The margin impact is visible. “EBITDA margin stood at 25.8% (up 95bps YoY) in Q3FY26, driven by a shift in product mix towards chronic therapies,” according to BP Equities. Chronic medications typically command better margins than acute therapies due to longer treatment durations, higher compliance, and less price sensitivity.
The Acute Segment Needs Time
The acute therapy business presents a different picture. “Acute therapies saw temporary softness due to internal corrections and field-force changes,” BP Equities reports, adding that “gastro and gynaecology showing recovery.” Systematix observes that “organic domestic branded formulation growth remains subdued owing to integration / execution challenges.”
The anti-infective segment faces broader industry headwinds. “Anti-infective segment under pressure, in line with broader industry trends,” BP Equities notes. This matters because acute and anti-infective therapies historically represented substantial portions of Mankind’s portfolio. While chronic therapies now comprise 39.3% of the mix, roughly 60% still comes from other categories facing varying degrees of growth pressure.
OTC Business Shows Recovery
The over-the-counter segment provides encouraging signs. “The OTC segment rebounded with 5.2% growth in Q3FY26 versus a 2.6% decline in Q2FY26,” BP Equities reports, suggesting momentum is building. Management “anticipates double-digit growth for the OTC business next year,” per BP Equities, indicating confidence in sustained improvement.
The quarterly performance shows some volatility. “India Consumer Healthcare business has reported sales of Rs 2,030 mn, up 5.2% YoY but down 10.2% QoQ,” Systematix reports.
Channel rationalization—cleaning up distribution and reducing excess inventory—creates near-term friction but supports healthier long-term growth. The gap between strong secondary sales (consumer purchases) and muted primary sales (company shipments to distributors) suggests disciplined inventory management.
BSV Acquisition Delivers
The Bharat Serums and Vaccines acquisition continues contributing positively. “Export revenue grew by 14% YoY in Q3FY26 and a substantial 50.8% YoY for the 9MFY26. Growth was primarily fueled by the healthy performance of the BSV international business,” BP Equities reports.
Systematix confirms the export performance: “Exports business reported sales of Rs 5,210 mn, up 14% YoY and up 1.6% QoQ, primarily driven by healthy growth in BSV international business.” The acquisition adds “a high-margin, high-entry-barrier portfolio in fertility, women’s health, and critical care,” according to BP Equities, providing both margin accretion and portfolio diversification.
The financial integration appears successful. “Company reduced net debt by Rs 5,000 mn during the quarter (Net Debt to EBITDA at 1.3x),” Systematix notes, demonstrating strong cash generation post-acquisition. Reducing leverage while maintaining growth investment shows effective capital allocation.
US Strategy Remains Selective
The US generics approach prioritizes quality over volume. “In the US market, Mankind (excluding BSV) has launched 4 new products in 9MFY26, bringing its total US product portfolio to 48,” BP Equities reports. This measured pace—four launches in nine months—reflects strategic discipline.
BP Equities elaborates: “Internationally, growth will remain selective and opportunity-led, with emphasis on complex, niche products without compromising EBITDA, implying domestic will continue to anchor profitability.” Mankind isn’t chasing market share at any cost; it’s building a focused portfolio of differentiated products while protecting margins.
Margin Quality Remains Strong
Despite mixed growth signals, profitability holds firm. “EBITDA stood at Rs 9,194 mn, up 12.7% YoY but flat QoQ. EBITDA margin was 25.8%, up 27 bps YoY and up 85 bps QoQ,” Systematix reports. The sequential margin expansion of 85 basis points is notable given the top-line declined 3.5% quarter-on-quarter.
Earnings show resilience even with one-time items affecting reported numbers. Systematix reports “PAT stood at Rs 4,087 mn, up 9.4% YoY but down 20.1% QoQ. PAT margin was 11.6%, down 21 bps YoY and 247 bps QoQ.” BP Equities provides context with adjusted PAT of Rs 5,205 million, “above our expectations of Rs 4,950 crores,” with “PAT margin rise 14.6% versus 14.1% in the previous quarter.”
The Domestic Foundation
India remains the core of Mankind’s business model. “Mankind Pharma’s revenue growth is driven by continued traction in the domestic formulations business (which remains ~85% of focus),” BP Equities states. Systematix confirms “India Pharmaceutical business recorded sales of Rs 28,432 mn, up 11.6% YoY but down 3.9% QoQ.”
This domestic concentration provides both stability and strategic focus. India’s pharmaceutical market offers secular growth from rising incomes, increasing health awareness, and expanding insurance coverage. Mankind’s extensive distribution network—built over decades—provides competitive advantage in reaching tier-2 and tier-3 markets where many competitors have limited presence.
Execution Adjustments Underway
The company is addressing operational challenges systematically. Systematix mentions “integration / execution challenges” affecting organic growth, while BP Equities notes “Acute therapies saw temporary softness due to internal corrections and field-force changes.”
Field-force restructuring—reshuffling sales representatives and territories—can temporarily disrupt doctor relationships and prescription patterns. Management appears committed to working through these adjustments. BP Equities reports specific actions: “Respiratory growth slightly softer vs industry due to gaps in cough portfolio; corrective actions underway.”
These gaps—missing products in therapeutic portfolios—create vulnerability but are addressable through product development or in-licensing. The company’s track record suggests capability to fill these holes systematically.
Valuation Reflects Quality and Expectations
The stock “is trading at a PE of 40.1x/31.7x on FY26e/27e EPS estimates,” per BP Equities. This premium multiple reflects several factors: strong margins, market-leading positions in growing chronic segments, successful M&A integration, and robust cash generation.
BP Equities values the stock at 38 times FY27 earnings, yielding a revised target price of Rs 2,501 (up 20%). The brokerage emphasizes “This integrated growth strategy, supported by substantial brand equity and balance sheet strength, provides high visibility of earnings expansion and positions the company as a long-term compounding opportunity in the Indian healthcare sector.”
Systematix takes a more conservative approach, valuing the stock at 35 times FY28 earnings for a target of Rs 2,467 while maintaining a “hold” rating. The brokerage notes: “We tweak our forecasts as we lower our expectations on domestic formulation growth” given the execution challenges and subdued organic growth in certain segments.
Both valuations acknowledge quality but differ on the appropriate premium given near-term growth uncertainty and integration challenges.
